Go Pro
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALPS
ALPS Group Inc Ordinary Share
$0.30
-7.7%		$0.53
$0.23
▼
$15.00
$53.25M-0.145,834 shs123,075 shs
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
$1.81
+3.7%		$1.80
$1.54
▼
$5.50
$64.10M1.25578,876 shs449,498 shs
BioStem Technologies, Inc. stock logo
BSEM
BioStem Technologies
$3.15
+5.0%		$3.60
$2.25
▼
$8.40
$56.22M0.1184,028 shs42,756 shs
Palatin Technologies stock logo
PTN
Palatin Technologies
$10.51
+5.6%		$9.86
$5.61
▼
$31.00
$18.71M0.6320,792 shs22,452 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALPS
ALPS Group Inc Ordinary Share
+0.06%-23.21%-35.96%-58.61%+32,019,900.00%
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-4.61%-5.38%+1.21%-9.04%-35.53%
BioStem Technologies, Inc. stock logo
BSEM
BioStem Technologies
-6.54%-20.63%-20.42%-29.62%-57.39%
Palatin Technologies stock logo
PTN
Palatin Technologies
+6.30%+35.19%+9.46%-30.27%+994,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALPS
ALPS Group Inc Ordinary Share
$0.30
-7.7%		$0.53
$0.23
▼
$15.00
$53.25M-0.145,834 shs123,075 shs
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
$1.81
+3.7%		$1.80
$1.54
▼
$5.50
$64.10M1.25578,876 shs449,498 shs
BioStem Technologies, Inc. stock logo
BSEM
BioStem Technologies
$3.15
+5.0%		$3.60
$2.25
▼
$8.40
$56.22M0.1184,028 shs42,756 shs
Palatin Technologies stock logo
PTN
Palatin Technologies
$10.51
+5.6%		$9.86
$5.61
▼
$31.00
$18.71M0.6320,792 shs22,452 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALPS
ALPS Group Inc Ordinary Share
+0.06%-23.21%-35.96%-58.61%+32,019,900.00%
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-4.61%-5.38%+1.21%-9.04%-35.53%
BioStem Technologies, Inc. stock logo
BSEM
BioStem Technologies
-6.54%-20.63%-20.42%-29.62%-57.39%
Palatin Technologies stock logo
PTN
Palatin Technologies
+6.30%+35.19%+9.46%-30.27%+994,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ALPS
ALPS Group Inc Ordinary Share
1.00
SellN/AN/A
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
2.60
Moderate Buy$11.67546.35% Upside
BioStem Technologies, Inc. stock logo
BSEM
BioStem Technologies
3.00
Buy$9.00185.71% Upside
Palatin Technologies stock logo
PTN
Palatin Technologies
3.00
Buy$55.00423.31% Upside

Current Analyst Ratings Breakdown

Latest PTN, ALPS, ANVS, and BSEM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2026
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/9/2026
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
7/7/2026
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$8.00
7/7/2026
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
7/6/2026
ALPS
ALPS Group Inc Ordinary Share
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/6/2026
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 8/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ALPS
ALPS Group Inc Ordinary Share
$4.86M10.12N/AN/A($3.10) per share-0.10
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/AN/AN/AN/A$0.64 per shareN/A
BioStem Technologies, Inc. stock logo
BSEM
BioStem Technologies
$292.21M0.19N/AN/AN/A∞
Palatin Technologies stock logo
PTN
Palatin Technologies
$4.49M4.17N/AN/A$5.95 per share1.77
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ALPS
ALPS Group Inc Ordinary Share
-$2.01M$0.330.97N/AN/AN/AN/AN/AN/A
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-$28.85M-$1.79N/AN/AN/AN/A-448.41%-272.53%N/A
BioStem Technologies, Inc. stock logo
BSEM
BioStem Technologies
N/A-$1.60N/AN/AN/AN/AN/AN/AN/A
Palatin Technologies stock logo
PTN
Palatin Technologies
-$17.31MN/AN/AN/AN/AN/A-141.40%-58.08%9/2/2026 (Estimated)

Latest PTN, ALPS, ANVS, and BSEM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/2/2026Q4 2026
Palatin Technologies stock logo
PTN
Palatin Technologies
-$1.20N/AN/AN/A$1.50 millionN/A
8/14/2026Q2 2026
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-$0.4533-$0.40+$0.0533-$0.40N/AN/A
8/12/2026Q2 2026
BioStem Technologies, Inc. stock logo
BSEM
BioStem Technologies
-$0.50-$0.52-$0.02N/A$6.35 million$7.90 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ALPS
ALPS Group Inc Ordinary Share
N/AN/AN/AN/AN/A
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/AN/AN/AN/AN/A
BioStem Technologies, Inc. stock logo
BSEM
BioStem Technologies
N/AN/AN/AN/AN/A
Palatin Technologies stock logo
PTN
Palatin Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ALPS
ALPS Group Inc Ordinary Share
N/A
0.36
0.27
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/A
1.27
1.27
BioStem Technologies, Inc. stock logo
BSEM
BioStem Technologies
N/AN/AN/A
Palatin Technologies stock logo
PTN
Palatin Technologies
N/A
5.04
5.04

Institutional Ownership

CompanyInstitutional Ownership
ALPS
ALPS Group Inc Ordinary Share
27.90%
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
15.83%
BioStem Technologies, Inc. stock logo
BSEM
BioStem Technologies
N/A
Palatin Technologies stock logo
PTN
Palatin Technologies
11.50%

Insider Ownership

CompanyInsider Ownership
ALPS
ALPS Group Inc Ordinary Share
0.81%
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
20.80%
BioStem Technologies, Inc. stock logo
BSEM
BioStem Technologies
N/A
Palatin Technologies stock logo
PTN
Palatin Technologies
7.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
ALPS
ALPS Group Inc Ordinary Share
N/A166.40 million165.05 millionN/A
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
334.65 million27.44 millionOptionable
BioStem Technologies, Inc. stock logo
BSEM
BioStem Technologies
N/A17.85 millionN/AN/A
Palatin Technologies stock logo
PTN
Palatin Technologies
301.78 million1.65 millionN/A

Recent News About These Companies

Palatin Technologies (NYSEAMERICAN:PTN) Trading Up 27.8% - Here's Why
August 13, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30957923
StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It
August 6, 2026  |  newsfilecorp.comN
Palatin Technologies Shareholders Back Governance and Incentive Plan
August 3, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/palatin-technologies-shareholders-back-governance-and-incentive-plan?utm_source=marketbeat.com&utm_medium=referral
Palatin to Begin Trading on Nasdaq Stock Exchange
May 18, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/palatin-to-begin-trading-on-nasdaq-stock-exchange-302774038.html
Palatin Is Betting on the Next Generation of Obesity Drugs (NYSE: PTN)
May 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RYTM-Q/pressreleases/1931399/palatin-is-betting-on-the-next-generation-of-obesity-drugs-nyse-ptn/
Palatin Technologies, Inc. (AMEX:PTN) Q3 2026 Earnings Call Transcript
May 14, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/palatin-technologies-inc-amexptn-q3-2026-earnings-call-transcript-1762055/
Palatin Technologies Earnings Call: Partnerships, Progress, Risks
May 13, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/palatin-technologies-earnings-call-partnerships-progress-risks?utm_source=marketbeat.com&utm_medium=referral
Palatin Technologies Inc (PTN) Q3 2026 Earnings Call Highlights: Strategic Advances Amidst ...
May 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/palatin-technologies-inc-ptn-q3-230342249.html
Palatin Technologies, Inc. (PTN) Q3 2026 Earnings Call Transcript
May 13, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4904082-palatin-technologies-inc-ptn-q3-2026-earnings-call-transcript
Palatin Technologies GAAP EPS of -$0.37, revenue of $3.9M
May 13, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4591952-palatin-technologies-gaap-eps-of--037-revenue-of-39m?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=news?source=MarketBeat
Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
May 13, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/palatin-reports-fiscal-third-quarter-2026-financial-results-and-provides-business-update-302770261.html
Palatin’s Case Strengthens as Rhythm’s FDA Approval Validates Hypothalamic Obesity Market (PTN)
March 22, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RYTM/pressreleases/880214/palatins-case-strengthens-as-rhythms-fda-approval-validates-hypothalamic-obesity-market-ptn/
Palatin Technologies, Inc. (PTN) Q2 2026 Earnings Call Transcript
February 17, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4870981-palatin-technologies-inc-ptn-q2-2026-earnings-call-transcript
Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
February 17, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/palatin-reports-second-quarter-fiscal-year-2026-financial-results-and-provides-corporate-update-302688156.html
Why Are Palatin Technologies (PTN) Shares Spiking After-Hours?
December 11, 2025  |  benzinga.comhttps://www.benzinga.com/markets/equities/25/12/49325529/why-are-palatin-technologies-ptn-shares-spiking-after-hours

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALPS Group Inc Ordinary Share NASDAQ:ALPS

$0.30 -0.02 (-7.68%)
Closing price 04:00 PM Eastern
Extended Trading
$0.28 -0.01 (-3.59%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ALPS Group Inc is a fully integrated platform encompassing biotechnology research, medical, and wellness services specializing in predictive, precision and preventive health management. It aims to provide its clientele with access to DNA and mRNA sequencing, cellular therapy, as well as wellness and anti-aging products and services.

Annovis Bio stock logo

Annovis Bio NYSE:ANVS

$1.80 +0.07 (+3.74%)
Closing price 03:59 PM Eastern
Extended Trading
$1.78 -0.03 (-1.66%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

BioStem Technologies stock logo

BioStem Technologies OTCMKTS:BSEM

$3.15 +0.15 (+5.00%)
As of 04:00 PM Eastern

BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.

Palatin Technologies stock logo

Palatin Technologies NYSEAMERICAN:PTN

$10.51 +0.56 (+5.63%)
Closing price 04:00 PM Eastern
Extended Trading
$10.59 +0.08 (+0.76%)
As of 05:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas